Role and clinical utility of pramipexole extended release in the treatment of early Parkinson’s disease

References

• OlanowCAgidYMizunoYLevodopa in the treatment of Parkinson’s disease: current controversiesMov Disord2004199997100515372588
   PubMed Web of Science ®Google Scholar
• HollowayRShoulsonIFahnSPramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trialArch Neurol20046171044105315262734
   PubMedGoogle Scholar
• GerfenCEngberTMahanLD1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neuronsScience19902504986142914322147780
   PubMed Web of Science ®Google Scholar
• HerreroMAugoodSHirschEEffects of L-DOPA on preproen-kephalin and preprotachykinin gene expression in the MPTP-treated monkey striatumNeuroscience1995684118911988544992
   PubMed Web of Science ®Google Scholar
• JolkkonenJJennerPMarsdenCL-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTPBrain Res Mol Brain Res19953222973077500841
   PubMedGoogle Scholar
• AntoniniATolosaEMizunoYYamamotoMPoeweWHA reassessment of risks and benefits of dopamine agonists in Parkinson’s diseaseLancet Neurol200981092993719709931
   PubMed Web of Science ®Google Scholar
• AntoniniAPoeweWFibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s diseaseLancet Neurol20076982682917706566
   PubMed Web of Science ®Google Scholar
• RascolOBrooksDKorczynADe DeynPClarkeCLangAA five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study GroupN Engl J Med2000342201484149110816186
   PubMed Web of Science ®Google Scholar
• GroupPSPramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study GroupJAMA2000284151931193811035889
   PubMed Web of Science ®Google Scholar
• OertelWWoltersESampaioCPergolide versus levodopa monotherapy in early Parkinson’s disease patients: The PELMOPET studyMov Disord200621334335316211594
   PubMed Web of Science ®Google Scholar
• HorstinkMTolosaEBonuccelliUReview of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson’s diseaseEur J Neurol200613111186120217038032
   PubMed Web of Science ®Google Scholar
• MiyasakiJMMartinWSuchowerskyOWeinerWJLangAEPractice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology2002581111711781398
   PubMed Web of Science ®Google Scholar
• GerlachMDoubleKArzbergerTLeblhuberFTatschnerTRiedererPDopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatumJ Neural Transm20031101119112714523624
   PubMed Web of Science ®Google Scholar
• KohnoYTakeuchiSPharmacological profiles and clinical effects of antiparkinsonian agent, pramipexoleNihon Yakurigaku Zasshi2004123642944015170083
   PubMedGoogle Scholar
• European Medicines AgencyAssessment Report for Sifrol EMEA/703892/2009LondonEuropean Medicines Agency2009 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000133/WC500049957.pdfAccessed August 9, 2010
   Google Scholar
• JennerPKönen-BergmannMSchepersCHaertterSPharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studiesClin Ther200931112698271120110012
   PubMed Web of Science ®Google Scholar
• PoeweWRascolOBaronePExtended-release pramipexole in early Parkinson disease: A 33-week randomized controlled trialNeurology20117775976621832218
   PubMed Web of Science ®Google Scholar
• HauserRASchapiraAHRascolORandomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson’s diseaseMov Disord201025152542254920669317
   PubMed Web of Science ®Google Scholar
• SchragASpottkeAQuinnNDodelRComparative responsiveness of Parkinson’s disease scales to change over timeMov Disord200924681381819199355
   PubMed Web of Science ®Google Scholar
• RascolOBaronePHauserRAEfficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson’s diseaseMov Disord201025142326233220669265
   PubMed Web of Science ®Google Scholar
• VillerFGuilleminFBriançonSMoumTSuurmeijerTvan den HeuvelWCompliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal studyJ Rheumatol199926102114212210529126
   PubMed Web of Science ®Google Scholar
• CramerJVachonLDesforgesCSussmanNMDose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trialEpilepsia19953611111111177588455
   PubMed Web of Science ®Google Scholar
• CramerJAA systematic review of adherence with medications for diabetesDiabetes Care20042751218122415111553
   PubMed Web of Science ®Google Scholar
• SackettDLHaynesRBGibsonESTaylorDWRobertsRSJohnsonALPatient compliance with antihypertensive regimensPatient Couns Health Educ197811182110238880
   PubMedGoogle Scholar
• LeopoldNAPolanskyMHurkaMRDrug adherence in Parkinson’s diseaseMov Disord200419551351715133814
   PubMed Web of Science ®Google Scholar
• GrossetKABoneIGrossetDGSuboptimal medication adherence in Parkinson’s diseaseMov Disord200520111502150716037924
   PubMed Web of Science ®Google Scholar
• GrossetKAReidJLGrossetDGMedicine-taking behavior: implications of suboptimal compliance in Parkinson’s diseaseMov Disord200520111397140416092116
   PubMed Web of Science ®Google Scholar
• HaynesRBDantesRPatient compliance and the conduct and interpretation of therapeutic trialsControl Clin Trials19878112193568692
   PubMedGoogle Scholar
• RichterAAntonSEKochPDennettSLThe impact of reducing dose frequency on health outcomesClin Ther200325823072335 discussion 230614512137
   PubMed Web of Science ®Google Scholar
• DavisKLEdinHMAllenJKPrevalence and cost of medication nonadherence in Parkinson’s disease: evidence from administrative claims dataMov Disord201025447448020131374
   PubMed Web of Science ®Google Scholar
• GrossetDAntoniniACanesiMAdherence to antiparkinson medication in a multicenter European studyMov Disord200924682683219191340
   PubMed Web of Science ®Google Scholar
• SchapiraAHBaronePHauserRAExtended-release pramipexole in advanced Parkinson disease: a randomized controlled trialNeurology201177876777421832216
   PubMed Web of Science ®Google Scholar